Dan Rosenblum has been a full-time stock trader since 1999 after leaving a job at a publicly held medical-device company. Rosenblum joined SharkInvesting.com that year and has been the online trading community's resident biotech expert ever since. Rosenblum writes the SharkBiotech.com newsletter, which has outperformed the S&P 500 and the Nasdaq Biotechnology Index every year since its inception in 2006. Rosenblum lives with his wife and kids in Rockland County, New York.
Recent Articles By The Author
Alexion Pharma: Negative Market Sentiment Creates Buying Opportunity
I think the market is obsessing over the Alexion negatives and not looking at the real potential for positive catalysts ahead.
Buying Bluebird's Blockbuster Potential at a Discount
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
Why I'm More Confident in Sarepta Than Ever Before
Biotech trader Dan Rosenblum believes the recent selloff in Sarepta is a tremendous buying opportunity.
Sarepta: Staying Long and Strong
Contributor Dan Rosenblum believes Sarepta's upside potential far outweighs the risk in the stock.
Sarepta Is Undervalued Even Without Eteplirsen Accelerated Approval
The exon-skipping drug technology is worth a lot more than just eteplirsen alone.
Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013
Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.
Still Bullish on BioMarin, Lexicon Pharma
TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.
Sunshine Heart: A Promising Treatment for Heart Failure Patients
Sunshine's C-Pulse is a heart-assist device for patients who fall between the cracks of current therapy.
Lexicon Pharma: Blockbuster Potential From A Diabetes Drug
Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.
Biomarin: Four Clinical Trial Events to Watch Before Year End
TheStreet contributor Dan Rosenblum explains why Biomarin is a very busy biotech.